Compare Nano-X Imaging Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 193 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.26
-35.52%
1.23
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.32%
0%
-19.32%
6 Months
-39.45%
0%
-39.45%
1 Year
-62.29%
0%
-62.29%
2 Years
-41.49%
0%
-41.49%
3 Years
-64.36%
0%
-64.36%
4 Years
-70.67%
0%
-70.67%
5 Years
-94.99%
0%
-94.99%
Nano-X Imaging Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
66.74%
EBIT Growth (5y)
-19.42%
EBIT to Interest (avg)
-58.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.62%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.99
EV to EBIT
-5.10
EV to EBITDA
-6.41
EV to Capital Employed
2.48
EV to Sales
25.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-48.61%
ROE (Latest)
-30.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 28 Schemes (10.39%)
Foreign Institutions
Held by 49 Foreign Institutions (7.5%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
3.00
2.80
7.14%
Operating Profit (PBDIT) excl Other Income
-11.50
-11.20
-2.68%
Interest
0.10
0.00
Exceptional Items
-0.00
0.00
Consolidate Net Profit
-14.70
-13.20
-11.36%
Operating Profit Margin (Excl OI)
-4,739.10%
-5,010.30%
27.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 7.14% vs -6.67% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -11.36% vs 6.38% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
11.30
9.90
14.14%
Operating Profit (PBDIT) excl Other Income
-44.80
-46.80
4.27%
Interest
0.00
0.00
Exceptional Items
-0.10
-5.40
98.15%
Consolidate Net Profit
-53.50
-60.80
12.01%
Operating Profit Margin (Excl OI)
-5,014.20%
-5,913.90%
89.97%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.14% vs 15.12% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 12.01% vs 46.29% in Dec 2023
About Nano-X Imaging Ltd. 
Nano-X Imaging Ltd.
Pharmaceuticals & Biotechnology
Nano-X Imaging Ltd is an Israel-based company that develops a digital X-ray source enabling a cost reduction of imaging systems.






